A Phase 4 interventional study of Alpelisib and Fulvestrant in Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in India. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer (aBC) with a PIK3CA mutation, whose disease had progressed on or after endocrine-based treatment.
The study was planned to enroll 40 participants. During the treatment phase, participants were treated with alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and on Day 1 of every cycle thereafter (± 3 days) in a 28-day cycle.
The planned duration of treatment was 6 months. Participants could be discontinued from treatment earlier due to unacceptable toxicity, disease progression, withdrawal of consent, or at the discretion of the investigator or the participant. For participants who were ongoing on treatment at the end of the planned study duration and who, in the opinion of the investigator, were still deriving clinical benefit from alpelisib, every effort was made to continue provision of study treatment via post-trial access (PTA).
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28 day cycle.
Drug: Alpelisib · Drug: Fulvestrant
Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
Also known as: BYL719
Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
Percentage of Participants With at Least One On-treatment Adverse Events (AEs)
Treatment-Emergent Adverse Events (TEAEs) were defined as the adverse events that occurred, or worsened, during the treatment period (i.e. from the first dose of treatment up to 30 days after the last dose of study drug).
Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Percentage of Participants With Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital anomaly or birth defect in the offspring of a study participant, or was an abnormal pregnancy outcome.
Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Percentage of Participants With Adverse Drug Reactions (ADRs)
An Adverse Drug Reaction (ADR) was defined as an adverse event (AE) that, in the investigator's judgment, was causally suspected to be related to the study treatment.
Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
This study was conducted at 16 centers in India.
| Milestone | Alpelisib + Fulvestrant |
|---|---|
| Started | 40 |
| Completed | 21 |
| Not completed | 19 |
| Withdrew: Adverse event | 4 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 1 |
| Withdrew: Progressive disease | 7 |
| Withdrew: Withdrawal by subject | 6 |
Treatment-Emergent Adverse Events (TEAEs) were defined as the adverse events that occurred, or worsened, during the treatment period (i.e. from the first dose of treatment up to 30 days after the last dose of study drug).
| Percentage of participants | Alpelisib + Fulvestrant |
|---|---|
| Percentage of Participants With at Least One On-treatment Adverse Events (AEs) | 100 (91.2 to 100) |
A Serious Adverse Event (SAE) was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital anomaly or birth defect in the offspring of a study participant, or was an abnormal pregnancy outcome.
| Percentage of participants | Alpelisib + Fulvestrant |
|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 25 (12.7 to 41.2) |
An Adverse Drug Reaction (ADR) was defined as an adverse event (AE) that, in the investigator's judgment, was causally suspected to be related to the study treatment.
| Participants | Alpelisib + Fulvestrant |
|---|---|
| Subjects with at least one TEAE related to Alpelisib | 39 |
| Subjects with at least one TEAE related to Fulvestrant | 7 |
Collected over On-treatment Adverse Events (AEs) and deaths were collected from first dose of study medication until the last dose plus 30 days safety follow-up, assessed up to approximately 7 months.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpelisib + Fulvestrant | 4/40 (10%) | 10/40 (25%) | 40/40 (100%) |
| Event | Alpelisib + Fulvestrant |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/40 |
| StomatitisGastrointestinal disorders | 2/40 |
| VomitingGastrointestinal disorders | 2/40 |
| FatigueGeneral disorders and administration site conditions | 2/40 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/40 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/40 |
| AnaemiaBlood and lymphatic system disorders | 1/40 |
| Cardio-respiratory arrestCardiac disorders | 1/40 |
| GastritisGastrointestinal disorders | 1/40 |
| NauseaGastrointestinal disorders | 1/40 |
| Event | Alpelisib + Fulvestrant |
|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 36/40 |
| StomatitisGastrointestinal disorders | 15/40 |
| DiarrhoeaGastrointestinal disorders | 14/40 |
| VomitingGastrointestinal disorders | 9/40 |
| Decreased appetiteMetabolism and nutrition disorders | 8/40 |
| NauseaGastrointestinal disorders | 7/40 |
| FatigueGeneral disorders and administration site conditions | 5/40 |
| PyrexiaGeneral disorders and administration site conditions | 5/40 |
| Weight decreasedInvestigations | 5/40 |
| AstheniaGeneral disorders and administration site conditions | 4/40 |
| Age, Continuous(Years) | Alpelisib + Fulvestrant |
|---|---|
| Mean | 54.9 ± 9.71 |
| Sex: Female, Male(Participants) | Alpelisib + Fulvestrant |
|---|---|
| Female | 40 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | Alpelisib + Fulvestrant |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 40 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2022 to primary completion in Jun 2025, 34 months.
Results were first posted in Jun 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpelisib
Multiple Endocrine Neoplasia Type 1